

## Lettre ouverte de 31 scientifiques internationaux pour «une enquête complète sur l'origine du SARS-CoV-2»

**EXCLUSIF** - «Le Figaro» publie une lettre ouverte de chercheurs qui durcissent le ton pour demander une investigation fouillée, «si possible avec la participation du gouvernement chinois».

**LE FIGARO**

**Le Point**

**La Libre** BELGIQUE

<https://www.lefigaro.fr/sciences/lettre-ouverte-de-31-scientifiques-internationaux-pour-une-enquete-complete-sur-l-origine-du-sars-cov-2-20210628>

[https://www.lepoint.fr/sante/covid-19-31-chercheurs-reclament-une-enquete-sur-les-origines-du-sars-cov-2--28-06-2021-2433150\\_40.php](https://www.lepoint.fr/sante/covid-19-31-chercheurs-reclament-une-enquete-sur-les-origines-du-sars-cov-2--28-06-2021-2433150_40.php)

<https://www.lalibre.be/debats/opinions/appel-a-une-enquete-complete-sur-l-origine-du-sars-cov-2-si-possible-avec-la-participation-du-gouvernement-chinois-60d9bf499978e26ce1e60c83>

4<sup>th</sup> open letter

28 June 2021

5 July 2021

# Foreign Ministry Spokesperson Wang Wenbin's Regular Press Conference

*Who are these so-called scientists? [..]*

*For those "scientists" who aim to craft a publicity stunt and attract attention, my advice is, to concentrate on scientific studies of their research fields, and do something that truly benefits humanity.*

*We believe that among those who signed the letter are some unwitting scientists who have been kept in the dark and taken advantage of.[..] Don't be blinded by doctored "truth", misled by politicized "science" or deceived by rumors and lies. Come back to science and reason.*



# Addendum to Lancet Letter 1

21 June 2021

## Addendum: competing interests and the origins of SARS-CoV-2

In February, 2020, 27 public health experts co-authored a Correspondence in *The Lancet* ("Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19"),<sup>1</sup> supporting health professionals and physicians in China during the early stages of the COVID-19 pandemic. In this letter, the authors declared no competing interests. Some readers have questioned the validity of this disclosure, particularly as it relates to one of the authors, Peter Daszak. In line with guidance from the International Committee of Medical Journal Editors, medical journals ask authors to report financial and non-financial relationships that may be relevant to interpreting the content of their manuscript.<sup>2</sup> There may be differences in opinion as to what constitutes a competing interest. Transparent reporting allows readers to make judgments about these interests. Readers, in turn, have their own interests that could influence their evaluation of the work in question. With these facts in mind, *The Lancet* invited the 27 authors of the letter to re-evaluate their competing interests. Peter Daszak has expanded on his disclosure statements for three pieces relating to COVID-19 that he co-authored or contributed to in *The Lancet*—the February, 2020, Correspondence,<sup>1</sup> as well as a Commission Statement<sup>3</sup> and a Comment<sup>4</sup> for the *Lancet* COVID-19 Commission. The updated disclosure statement from Peter Daszak is:

"PD's remuneration is paid solely in the form of a salary from EcoHealth Alliance, a 501(c)(3) non-profit organisation. EcoHealth Alliance's mission is to develop science-based solutions to prevent pandemics and promote conservation. Funding for this work comes from a range of US Government funding agencies and non-governmental sources. All past and current funders are listed publicly, and full financial accounts are filed annually and published. EcoHealth Alliance's work in China was previously funded by the US National Institutes of Health (NIH) and the United States Agency for International Development (USAID). Neither PD nor EcoHealth Alliance have received funding from the People's Republic of China. PD joined the WHO-China joint

global study on the animal origins of SARS-CoV-2 towards the end of 2020 and is currently a member. As per WHO rules, this work is undertaken as an independent expert in a private capacity, not as an EcoHealth Alliance staff member. The work conducted by this study was published in March, 2021. EcoHealth Alliance's work in China includes collaboration with a range of universities and governmental health and environmental science organisations, all of which are listed in prior publications, three of which received funding from US federal agencies as part of EcoHealth Alliance grants or cooperative agreements, as publicly reported by NIH. EcoHealth Alliance's work in China is currently unfunded. All federally funded subcontractees are assessed and approved by the respective US federal agencies in advance and all funding sources are acknowledged in scientific publications as appropriate. EcoHealth Alliance's work in China involves assessing the risk of viral spillover across the wildlife-livestock-human interface, and includes behavioural and serological surveys of people, and ecological and virological analyses of animals. This work includes the identification of viral sequences in bat samples, and has resulted in the isolation of three bat SARS-related coronaviruses that are now used as reagents to test therapeutics and vaccines. It also includes the production of a small number of recombinant bat coronaviruses to analyse cell entry and other characteristics of bat coronaviruses for which only the genetic sequences are available. NIH reviewed the planned recombinant virus work and deemed it does not meet the criteria that would warrant further specific review by its Potential Pandemic Pathogen Care and Oversight (P3CO) committee. All of EcoHealth Alliance's work is reviewed and approved by appropriate research ethics committees, Institutional Animal Care and Use Committee, Institutional Review Boards for biomedical research involving human subjects, P3CO oversight administrators, and biosafety committees, as listed on all relevant publications."

The Correspondence, Commission Statement, and Comment are linked online to this notice of addendum.

We declare no competing interests.

*Editors of The Lancet*

*The Lancet*, London EC2Y 5AS, UK

1 Calisher C, Carroll D, Colwell R, et al. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19. *Lancet* 2020; **395**: e42–43.

Peter Daszak's competing interests  
(no mention of WIV)

Daszak 'rejected' from Lancet COVID-19 commission – .

June 22, 2021

148 0

P Daszak no longer appears among commissioners of the Lancet Covid-19 commission

<https://covid19commission.org/commissioners>

# Lancet Letter 2

---

5 July 2021

## Science, not speculation, is essential to determine how SARS-CoV-2 reached humans

On Feb 19, 2020, we, a group of physicians, veterinarians, epidemiologists, virologists, biologists, ecologists, and public health experts from around the world, joined together to express solidarity with our professional colleagues in China.<sup>1</sup> Unsubstantiated allegations were

reaffirm our expression of solidarity with those in China who confronted the outbreak then, and the many health professionals around the world who have since worked to exhaustion, and at personal risk, in the relentless and continuing battle against this virus. Our respect and gratitude have only grown with time.

The second intent of our original Correspondence was to express our working view that SARS-CoV-2 most likely originated in nature and not in a laboratory, on the basis of early

within nature or have reached the community via an alternative route, at the onset of the pandemic. Allegations of laboratory origin are of no help, as they do not provide access to information for a proper assessment of the path of the virus to a human population. Recrimination has not helped to encourage international and collaboration.<sup>9</sup> The virus may emerge anywhere, and the only way to prevent it is through transparency and collaboration.

[https://doi.org/10.1016/S01406736\(21\)014197](https://doi.org/10.1016/S01406736(21)014197)

Charles H Calisher, Dennis Carroll, Rita Colwell, Ronald B Corley, Peter Daszak, Christian Drosten, Luis Enjuanes, Jeremy Farrar, Hume Field, Josie Golding, Alexander E Gorbalenya, Bart Haagmans, James M Hughes, \*Gerald T Keusch, Sai Kit Lam, Juan Lubroth, John S Mackenzie, Larry Madoff, Jonna Keener Mazet, Stanley M Perlman, Leo Poon, Linda Saif, Kanta Subbarao, Michael Turner

**In Letter 1 but not Letter 2:**

Peter Palese, Bernard Roizman

# Critical Review on the Origins

zenodo

Search



Upload

Communities

<https://zenodo.org/record/5075888#.YPAcpi0Rp-r>

July 7, 2021

Preprint Open Access

## The Origins of SARS-CoV-2: A Critical Review

Holmes, Edward C; Goldstein, Stephen A; Rasmussen, Angela L; Robertson, David L; Crits-Christoph, Alexander; Wertheim, Joel O; Anthony, Simon J; Barclay, Wendy S; Boni, Maciej F; Doherty, Peter C; Farrar, Jeremy; Geoghegan, Jemma L; Jiang, Xiaowei; Leibowitz, Julian L; Neil, Stuart J D; Skern, Tim; Weiss, Susan R; Worobey, Michael; Andersen, Kristian G; Garry, Robert F; Rambaut, Andrew

The Origins of SARS-CoV-2: A Critical Review

Holmes et al.

Since the first reports of a novel SARS-like coronavirus in December 2019 in Wuhan, China, there has been intense interest in understanding how SARS-CoV-2 emerged in the human population. Recent debate has coalesced around two competing ideas: a "laboratory escape" scenario and zoonotic emergence. Here, we critically review the current scientific evidence that may help clarify the origin of SARS-CoV-2.



Francisco de Asis @franciscodeasis · Jul 7

Interesting to see how the new pre-print "The Origins of SARS-CoV-2: A Critical Review" (Holmes et al., 2021) debunks the first patient of the China-WHO report

mentary Table S2. Early cases linked to genome sequer

Collection date	age/sex	Sequence name	GISAI ID
6 2019-12-30	41M	Wuhan/IPBCAMS-WH-03/2019	EPI_ISL_403930
5 2019-12-24	65M	Wuhan/IPBCAMS-WH-01/2019	EPI_ISL_402123
7 2019-12-26	44M	Wuhan/WH01/2019	EPI_ISL_406798
9 2019-12-30	32M	Wuhan/HBCDC-HB-02/2019	EPI_ISL_412898
0 2019-12-30	61M	Wuhan/IPBCAMS-WH-05/2020	EPI_ISL_403929
0 2019-12-26	41M	Wuhan/Hu-1/2019	EPI_ISL_402125
0 2020-01-02	39M	Wuhan/WHU01/2020	EPI_ISL_406716
0 2019-12-30	56M	Wuhan/IME-WH04/2019	EPI_ISL_529216
2 2020-01-02	21F	Wuhan/WHU02/2020	EPI_ISL_406717
3 2019-12-30	49F	Wuhan/IPBCAMS-WH-02/2019	EPI_ISL_403931
3 2019-12-30	62F	Wuhan/IPBCAMS-WH-04/2019	EPI_ISL_403929

Table 6. Details of genomic sequencing of 13 early cases

ID	Onset date	Collection date	View virus	Mutation profile from submitted genome sequences	Mutation profile identified in analysis	Sequencing platform	Sequencing depth	Reads error %
501	2019-12-08	2019-12-08	Genomic Sciences (GISAID)	7866	7866/2507	Illumina NextSeq 500	409	0.01
502	2019-12-13	2019-12-24	Beckm/2019-12-24-2019-12-24	2776, 1388, 1907	>1	Illumina NextSeq 500	2278	0.00
503	2019-12-17	2019-12-26	WHU1	4968, 11764	NA	DNBSEQ		
	2019-12-20		Beckm/2019-12-20-2019-12-20	24325	24325	NGS	4720	0.01
	2019-12-20		WHU02	21106, 24325	21106, 24325	Illumina MiSeq, DNBSQ 2000	15	0.00
504	2019-12-19		Wuhan/WHU01/2019	7	7	Ion Torrent S5Plus	149	0.76
	2019-12-20		Beckm/2019-12-20-2019-12-20	24325	24325	Illumina MiSeq	475	0.01

Table 7. The overview of sequences from early patients (with onset date before 31 December 2019)

Sample ID	Sequence ID	Relation to the Huanan market	Staff	Onset date	Collection date	Mutations (gene name)	Lineage
S01	EPI_ISL_403928	Visitor to another market		8 Dec	1 Jan 2020	7866 (ORF1a)	L/B
S02	EPI_ISL_402123	Vendor	Seafood	13 Dec	24 Dec	0	L/B
S03	EPI_ISL_406798	Purchaser		17 Dec	26 Dec	6968 (ORF1a), 11764 (ORF1a)	L/B
S04	NMDC6001-20070-001	Vendor	Frozen meats	19 Dec	30 Dec	24325 (S)	L/B

## A response to "The Origins of SARS-CoV-2: A Critical Review"

Alina Chan 2 days ago · 35 min read

By Alina Chan, on Twitter @ayjchan



# Hearing House Science, Space, and Technology Committee



July 14, 2021

## COVID-19

Get the latest information from the WHO about coronavirus.

 See more resources on Google 

Hearing: Principles for Outbreak Investigation: COVID-19 and Future Infectious...(EventID

July 14, 2021



AMERICAN  
SOCIETY FOR  
MICROBIOLOGY

Home / Articles / [Don't Restrict Valid Pathogen Research, ASM & Partners Warn Congress](#)

## Don't Restrict Valid Pathogen Research, ASM & Partners Warn Congress

July 14, 2021

[SHARE THIS](#) 

<https://asm.org/Articles/Policy/2021/July-21/Science-Should-Lead-COVID-19-Investigation,-ASM-Te>